About Epigenomics
Epigenomics is a company based in Berlin (Germany) founded in 1998. Epigenomics has raised $46.67 million across 12 funding rounds from investors including European Commission, 3i Group and European Union. The company has 32 employees. Epigenomics offers products and services including Investment Services. Epigenomics operates in a competitive market with competitors including Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others.
- Headquarter Berlin, Germany
- Employees 32
- Stage Public
- SectorsHealthcare
- Website epigenomics.com
- Social LinkedIn X
- Legal Name Epigenomics Ag
- Total Equity Funding$46.67M (USD)
in 12 rounds
- Latest Funding Round$6.77M (USD), Post-IPO
Jan 2021
- InvestorsEuropean Commission
& 9 more
- Employee Count32
Products & Services of Epigenomics
Epigenomics offers a comprehensive portfolio of products and services, including Investment Services.
Services for acquiring and managing investments in cancer detection technologies.
Funding Insights of Epigenomics
Epigenomics has successfully raised a total of $46.67M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.77 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.67M
- Total Rounds 12
- Last Round Post-IPO — $6.77M
- First Round $24.07M
(Nov 2000)
- Investors Count 10
Latest 10 of 12 funding rounds of Epigenomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $6.77M | Post-IPO | – | – | |
| Mar 2020 | – | Post-IPO | – | – | – |
| Nov 2019 | $5.3M | Post-IPO | – | – | |
| Jan 2018 | $276,873 | Grant | – | – | |
| Dec 2017 | $3.32M | Grant | – | – | |
| Jul 2015 | $3.06M | Grant | – | – | |
| Apr 2015 | $3.06M | Grant | – | – | |
| Oct 2014 | $5.38M | Post-IPO | – | – | |
| Dec 2013 | $21.02M | Post-IPO | – | – | – |
| Aug 2013 | $6.67M | Debt – Conventional | – | – | – |
10 investors in total: 10 institutional.
Investors in Epigenomics
Epigenomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include European Commission, 3i Group and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on investing in multiple sectors | 1991 | deutsche-balaton.de | Heidelberg, Germany | |
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Provider of products and services for clinical diagnosis, genomics, and proteomics | 1994 | biochain.com | Hayward, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Institution of the European Union responsible for upholding the EU treaties | 1958 | ec.europa.eu | Brussels, Belgium | |
Wellcome is a global charitable foundation focused on health research. | – | wellcome.ac.uk | London, United Kingdom | |
- | – | dvcg.de | - | |
Invests in biotech firms developing life-saving drugs and technologies. | – | mpmcapital.com | - |
Investor details for Epigenomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Epigenomics
1 people are tracked at Epigenomics (1 in leadership); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Greg Hamilton | CEO | Leadership |
Complete people profiles for Epigenomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Epigenomics
4 dated milestones of Epigenomics across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Epigenomics is founded.
- Funding First funding round of $24.1M.
- Funding Latest funding round, Post-IPO, of $6.8M.
- IPO Lists on the stock exchange (IPO).
Competitors of Epigenomics
Epigenomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $3.22B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection |
Detailed competitors of Epigenomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Epigenomics
The website of Epigenomics (epigenomics.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 115.1% vs previous month
Websites whose visitors overlap most with Epigenomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
roadmapepigenomics.org | roadmapepigenomics.org | 100% | – | – | – |
labnext.com | labnext.com | 94% | – | – | – |
| biocompanion.com | 94% | – | – | View details | |
| genta.com | 94% | 680.7K | – | View details | |
intrexon.com | intrexon.com | 94% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Epigenomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Epigenomics
Complete news archive for Epigenomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Epigenomics
10 companies that operate in the same segment as Epigenomics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Epigenomics
Epigenomics was founded in 1998 and raised its 1st funding round 2 years after it was founded.
Epigenomics is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Greg Hamilton is the current CEO of Epigenomics.
Epigenomics is a funded company, having raised a total of $46.67M across 12 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $6.67M, raised on Nov 2000.
Epigenomics has 32 employees.
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer. Their product portfolio includes Epi proColon, a blood-based test for the early detection of colorectal cancer and Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer.Their development pipeline also contains tests for screening, monitoring, diagnosis and prognosis assessment in colorectal and lung cancer.
Epigenomics's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
Epigenomics offers Investment Services.
Epigenomics has 10 investors. Key investors include European Commission, 3i Group, European Union, Abingworth, and Deutsche Balaton.
Epigenomics operates through Epigenomics Ag.